Table 3.

Health care utilization by overall adherence with tobramycin inhalation solution, N = 804.

	Low utilization ≤2 cycles (n = 570)	Medium utilization >2 to <4 cycles (n = 180)	High utilization ≥4 cycles (n = 54)
Patients hospitalized (%)	42.9%	40.6%	25.9%
Median inpatient costs, IQR	$23,619	$16,814	$20,610
	$11,566-55,446	$9,527-41,021	$8,076-64,799
Median outpatient costs, (excludes drug costs) IQR	$6,317	$5,463	$4,033
	$2,564-14,423	$2,410-13,653	$2,159-8,444
Median outpatient prescription drug costs, IQR	$17,850	$35,892	$46,708
	$10,353-27,260	$27,482-46,768	$35,125-60,969
% of outpatient prescription drug costs for TIS, median	29%	41%	45%

IQR = interquartile range; TIS = tobramycin inhalation solution